Evidence map›Paper›PMID 34853351›Full record

ArticleScientific reports2021

Losartan improves intestinal mucositis induced by 5-fluorouracil in mice.

Maisie Mitchele Barbosa Oliveira, Aurigena Antunes de Araújo, Susana Barbosa Ribeiro, Polyana Crislayne Moreira de Sales Mota, Vitória Barros Marques, Conceição da Silva Martins Rebouças, Jozi Godoy Figueiredo, Patrícia Batista Barra, Gerly Anne de Castro Brito, Renata Ferreira de Carvalho Leitão and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. The beneficial effects ofFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Maisie Mitchele Barbosa OliveiraPost Graduate Program Biotechnology-RENORBIO, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Aurigena Antunes de AraújoPost Graduate Program in Pharmaceutical Science, Post Graduate Program Dental Sciences, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Susana Barbosa RibeiroJunior Postdoctoral Student CNPq-Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Polyana Crislayne Moreira de Sales MotaBiosciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Vitória Barros MarquesBiosciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Conceição da Silva Martins RebouçasDepartment of Morphology, Faculty of Medicine, Federal University of Ceará (UFC), Fortaleza, CE, Brazil.
Jozi Godoy FigueiredoDepartment of Biochemistry, Faculty of Vale do São Lourenço (EDUVALE), Jaciara, MT, Brazil.
Patrícia Batista BarraPost Graduate Program in Biology Teaching in National Network-PROFBIO, Department of Biomedical Sciences, State University of Rio Grande do Norte (UERN), Mossoró, RN, Brazil.
Gerly Anne de Castro BritoPost Graduate Program Morphofunctional Sciences, Post Graduate Program Medical Sciences, Department of Morphology, Faculty of Medicine, Federal University of Ceará (UFC), Fortaleza, CE, Brazil.
Renata Ferreira de Carvalho LeitãoPost Graduate Program Morphofunctional Sciences, Department of Morphology, Faculty of Medicine, Federal University of Ceará (UFC), Fortaleza, CE, Brazil.
Gerlane Coelho Bernardo GuerraPost Graduate Program Biochemistry and Molecular Biology, Post Graduate Program Pharmaceutical Science, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Caroline Addison Carvalho Xavier de MedeirosPost Graduate Program Biotechnology-RENORBIO, Post Graduate Program Biochemistry and Molecular Biology, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil. carolaufrn@gmail.com.
Universidade Federal do Rio Grande do Norte · BRUniversidade Federal do Ceará · BRUniversidade do Estado do Rio Grande do Norte · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation. In search of new pharmacological alternatives that minimize your symptoms, this work set out to study the effect of losartan (LOS), a receptor type I (AT1) angiotensin II antagonist, on intestinal mucositis induced by 5-FU. Intestinal mucositis was induced by a single intraperitoneal administration of 5-FU (450 mg/kg) in Swiss mice. Losartan (5, 25 or 50 mg/kg) or saline was orally administered 30 min before 5-FU and daily for 4 days. On 4th day, the animals were euthanized and segments of small intestine were collected to evaluate histopathological alterations (morphometric analysis), concentration of inflammatory cytokines, oxidative stress markers and genic expression of NF-κB p65, Fn-14 and TWEAK. Weight evaluation and changes in leukogram were also analyzed. 5-FU induced intense weight loss, leukopenia and reduction in villus height compared to saline group. Losartan (50 mg/kg) prevented 5-FU-induced inflammation by decreasing in the analyzed parameters compared to the 5-FU group. Our findings suggest that 50 mg/kg of losartan prevents the effects of 5-FU on intestinal mucosa in mice.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsAntimetabolites, AntineoplasticCytokinesFemaleFluorouracilInflammationIntestinal MucosaLosartanMiceMucositisOxidative StressAngiotensin II Type 1 Receptor BlockersAntimetabolites, AntineoplasticCytokinesFluorouracilLosartan

Identifiers

PMID34853351
PMCPMC8636633
OpenAlexW3216224397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.